HHS will not act against a licensed pharmacy compounding MOTS-c under its conditions; it is a non-binding draft, not FDA approval 12.
Covered forms only: subcutaneous or intramuscular injectable dosage forms 3. One peptide per product; no blends 4.
Licensed pharmacies that have announced it, as of November 18, 2026: Olympia Pharmaceuticals 5.
On this page
- Where MOTS-c stands
- Which forms of MOTS-c the policy covers
- Licensed pharmacies that have announced MOTS-c
- The prescription route, step by step
- What it costs, and the alternatives
- What FDA found when it reviewed MOTS-c
- Frequently asked questions
- Related on Grey Peptides
- Sources
Where MOTS-c stands
Status checked November 18, 2026. The HHS policy is a draft, non-binding promise not to enforce, open to change; none of the six is FDA-approved or on the 503A bulks list. We re-read the policy and every pharmacy announcement on this page at source at least every 60 days.
On October 30, 2026 HHS, FDA's parent department, published a notice saying it "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician" compounding a drug from one of six peptides, MOTS-c among them, when every condition of its policy is met 1. The notice calls the policy a draft and says it "is not binding on HHS or the public" 1. It lasts until FDA decides, in a final rule, whether MOTS-c goes on the 503A bulks list 4.
So a prescription for MOTS-c can now be filled by a licensed 503A pharmacy that meets the conditions, without HHS acting against it. That is not approval. The Federation of State Medical Boards puts it plainly: "The policy provides conditional federal non-enforcement, not FDA approval", and it "does not amend state medical or pharmacy practice acts" 2. The policy does not cover vials sold as 'research use only' (our fact check).
Which forms of MOTS-c the policy covers
Appendix B describes MOTS-c acetate and limits it to "subcutaneous or intramuscular injectable dosage forms" 3.
Covered:
- Injection under the skin (subcutaneous)
- Injection into muscle (intramuscular)
Not covered, even from a licensed pharmacy:
- Any oral, nasal or topical form
- Any blend with a second peptide
Of the seven peptides FDA reviewed in July, MOTS-c had the thinnest file: no nonclinical data to inform safety for the proposed uses and no clinical studies in people. 3
Licensed pharmacies that have announced MOTS-c
As of November 18, 2026, 1 state-licensed pharmacy has announced MOTS-c under the policy, in its own release:
| Pharmacy | Type | Licensed in | Announced | What it said about MOTS-c |
|---|---|---|---|---|
| Olympia Pharmaceuticals | 503A pharmacy (the company also runs an FDA-registered 503B outsourcing facility) | "Olympia holds active licenses in 49 states" (its own release; the release does not say which state is missing). | November 12, 2026 5 | Named among the peptides it plans to evaluate and roll out after BPC-157; no separate date. |
We name a pharmacy here only if it is state-licensed and has itself announced compounding one of the six under the policy, and we link its own announcement. Naming one is not a recommendation: we have not inspected any pharmacy, tested its products or compared prices. Telehealth companies have also said they will offer some of these peptides; we name one only when its own announcement names the licensed pharmacy that fills its prescriptions, and none we read as of November 18, 2026 did. Check any pharmacy's license with your state board of pharmacy.
The prescription route, step by step
- A prescriber. A licensed prescriber decides MOTS-c is right for you and writes a prescription for you by name; the policy keeps the law's patient-specific prescription requirement 4. "Federal non-enforcement does not establish that treatment meets the standard of care", the FSMB adds, so the prescriber still has to justify it 2.
- Your state. State law still decides what a pharmacy or physician may do; a physician must "separately confirm that state law permits the activity" 2. The pharmacy must be licensed where you live.
- A 503A pharmacy. The policy covers state-licensed pharmacies, federal facilities and licensed physicians 1; lawyers reading it note that it does not cover 503B outsourcing facilities 6.
- What you receive. One peptide, in a covered form, labelled "This is a compounded drug product. Not for resale.", with at most an FDA-cleared syringe as the device 4.
- If something goes wrong. The pharmacy must report serious adverse events and quality problems to FDA and the states 4; you can report one yourself through FDA's MedWatch.
What it costs, and the alternatives
No licensed pharmacy named on this page has published a price for MOTS-c (the release from Olympia Pharmaceuticals gives none) 5. Expect two costs: the prescriber's visit and the compounded product. What a compounded product adds over a grey-market vial is what the conditions require: a registered maker, a tested batch, a label, a prescriber and a reporting duty. When prices are published, our price-per-mg calculator compares any two offers.
For obesity, FDA-approved drugs exist; our cost guide lists their makers' published cash prices. 7 Our cost guide lists approved options by condition.
What FDA found when it reviewed MOTS-c
FDA reviewed MOTS-c for obesity and osteoporosis before the July 2026 advisory committee. FDA proposes not adding either MOTS-c substance to the 503A Bulks List. Of the seven, this evaluation records the emptiest file: no nonclinical data to inform safety for the potential clinical uses, and no clinical studies of safety or effectiveness in humans. 7
- Characterisation. FDA says MOTS-c (free base) is not well characterised, citing nomenclature inconsistency and the absence of quality control attributes — impurities, aggregates, endotoxins — in the published literature, plus no Certificate of Analysis in the nomination. It also flags missing water-solubility data, which prevented a conclusion on whether solubility would affect the proposed formulation.
- Historical use. FDA describes the extent of use in compounding as unknown.
- Effectiveness. No clinical studies assessing effectiveness in humans.
- Safety. No available nonclinical data to inform safety considerations for potential clinical uses, and no clinical studies in humans. FDA notes it lacks the information needed to assess immunogenicity risk for a 16-amino-acid peptide.
The committee voted 7–5, 2 abstentions to recommend it for the 503A bulks list anyway 7. FDA has not acted on that vote; the HHS policy is a separate, interim step. Full detail is on our PCAC hub and the MOTS-c encyclopedia entry.
Frequently asked questions
Is MOTS-c legal now?
Not in the sense of approved. HHS says it will not take enforcement action against a licensed pharmacy that compounds MOTS-c for a named patient under its policy's conditions, and the policy is a non-binding draft that can change. MOTS-c is not FDA-approved, and the policy does not cover research-use-only sales.12
Can I get MOTS-c with a prescription?
Yes, from a state-licensed 503A pharmacy that meets the policy's conditions, if your state allows it. The pharmacy may make it only in the covered forms: subcutaneous or intramuscular injectable dosage forms.23
Which pharmacies compound MOTS-c?
As of November 18, 2026, Olympia Pharmaceuticals has announced it in its own release; we list only licensed pharmacies with their own announcement.5
Can a pharmacy mix MOTS-c with another peptide?
No. The policy covers a product with a single active ingredient from its list, so any blend of two peptides is outside it.4
Related on Grey Peptides
Sources
The Federal Register notice, the HHS policy and its appendices, the FSMB FAQ and FDA's meeting page are primary documents; the pharmacy release is the company's own statement; the law-firm advisory is analysis. All read November 18, 2026. Not legal or medical advice.
- Federal Register: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Office of the Secretary, HHS. Notice of availability, 91 FR 68526-68527, October 30, 2026; docket HHS-OASH-2026-0496; FR Doc. 2026-22192. Read in full November 18, 2026. Source
- Federation of State Medical Boards: FAQs on the HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, November 10, 2026 (hosted by the Alabama Board of Medical Examiners). Read November 18, 2026. Source
- HHS: the policy with Appendix A (the six peptides) and Appendix B (identity and routes of administration), PDF. Read November 18, 2026. Source
- HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (policy text, undated PDF). Read November 18, 2026. Source
- Olympia Pharmaceuticals: Olympia Pharmaceuticals to compound select peptides under HHS interim enforcement policy. Company press release, GlobeNewswire, Orlando, Florida, November 12, 2026. The company's own statement. Read November 18, 2026. Source
- Arnold & Porter (law firm): HHS announces draft enforcement discretion policy paving way for pharmacies, client advisory, November 2026. Legal analysis, not the policy itself. Read November 18, 2026. Source
- FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee, meeting page with FDA's briefing document for each peptide. Our compound-by-compound summary is on the PCAC hub. Source
This page explains a federal enforcement policy; it is not legal or medical advice. The policy is non-binding and can change, and none of these peptides is FDA-approved. Naming a pharmacy is not a recommendation. Grey Peptides sells nothing and takes no payment from pharmacies.